Since RUNX3 has been shown as an independent prognostic factor for overall 5-year survival and disease-free survival in patients, it could be used for prognosis, and possibly as a therapeutic target for HCC [44]. This evidence concerns the gene RUNX3 and hepatocellular carcinoma.